 NRx Pharmaceuticals Inc NASDAQ: NRXP has initiated a phase 2b dose-confirmatory trial of the BriLife vaccine against COVID-19 in the Nation of Georgia. The vaccine is developed by the Israel Institute for Biological Research IIBR. 